Brief: Neubase Therapeutics Reports Q1 Loss Per Share Of $0.24
11/02/2022 24:05
Feb 10 (Reuters) - NeuBase Therapeutics Inc NBSE.O :
* NEUBASE THERAPEUTICS REPORTS BUSINESS UPDATE AND FINANCIAL
RESULTS FOR THE FIRST QUARTER OF FISCAL YEAR 2022
* Q1 LOSS PER SHARE $0.24
* NEUBASE THERAPEUTICS INC- WE EXPECT TO FILE AN WITH FDA IN
Q4
CY2022 FOR DEVELOPMENT CANDIDATE FOR OUR MYOTONIC DYSTROPHY TYPE
1 (DM1) PROGRAM
Source text for Eikon: ID:nGNX1J19GT
Further company coverage: NBSE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on NeuBase Therapeutics
See all newsBrief: Neubase Therapeutics, On May 2, Was Notified By Nasdaq On Not Regained Compliance With Minimum Bid Price Requirement
Brief: Neubase Therapeutics Announces Receipt Of Notice From Nasdaq
U.S. STOCKS ON THE MOVE-TPG, R1 RCM, Zoom
U.S. STOCKS ON THE MOVE-Micron, Krystal Biotech, Pilgrim's Pride
U.S. STOCKS ON THE MOVE-Domino's Pizza, Voyager, Freshpet